Effects of probucol and EPA on lipid component of HDL particles
- Conditions
- Familial Hypercholesterolemia Dyslipidemia
- Registration Number
- JPRN-UMIN000024187
- Lead Sponsor
- Cardiology, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
(A)Probucol-treated group 1)Taken probucol previously 2)Taking cyclosporin 3)Allergic to probucol 4)TG>400 mg/dL 5)HbA1c>8% 6)Frequent multifocal premature ventricular contraction 7)Atrial fibrillation 8)QTc>450msec(male),>470msec(female)on the ECG 9)Congestive heart failure or unstable angina 10)Participating in other trials 11)Pregnant (or might be pregnant) or lactating 12)The doctor decided to be inadequate for participating in this trial (B) EPA-treated group 1)Hemodialysis 2)Liver dysfunction 3)Active malignant diseases 4)Scheduled to undergo coronary angiography or CABG 5)Severe heart failure 6)ACS within 3 months 7)PCI or CABG within 3 months 8)HbA1c>8% 9)Secondary dyslipidemia or taking omega3 agents 10)Bleeding or bleeding tendency 11)Having past side effects for omega3 agents 12)Participating in other trials 13)Pregnant (or might be pregnant) or lactating 14)The doctor decided to be inadequate for participating in this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of lipid species in HDL particles after the treatment of probucol or EPA
- Secondary Outcome Measures
Name Time Method